FDA added a boxed warning to the osteoporosis drug denosumab (Prolia). The agency’s review of the drug indicated risks that warrant new prescribing information. For patients with chronic kidney disease (CKD)—especially those on dialysis or those with a concomitant diagnosis of mineral and bone disorder—FDA said they could develop severe hypocalcemia, or very low levels of calcium in the blood.

CDC’s adult immunization schedule for 2024, which was published in the Annals of Internal Medicine on January 12, 2024, includes updates for several vaccines, including those for respiratory syncytial virus (RSV), meningitis, mpox, and COVID-19. The immunization schedule is based on the recommendations of CDC’s ACIP.

Early intervention with tecovirimat may stop an mpox infection from advancing to the stages of severe disease in people living with HIV (PWH), new research suggests.

Paxlovid did not reduce the risk of developing long COVID in vaccinated, nonhospitalized adults, according to new data published in the Journal of Medical Virology.

Effective immediately, FDA has changed the labels on two medications used to bring down LDL cholesterol levels: bempedoic acid (Nexletol) and bempedoic acid/ezetimibe (Nexlizet).